Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
How to inject: sites, needles, technique Subcutaneous (SQ)
The once-daily pill is now accessible through retail pharmacies across the U.S.(Source: Segments Covered in the Report By Drug Type Semaglutide (Wegovy/Ozempic) Tirzepatide (Zepbound/Mounjaro) Liraglutide (Saxenda) Emerging Oral GLP-1s By Route of Administration Parenteral (Injectable) Oral (Tablets/Pills) By Target Indication Type 2 Diabetes Obesity/Chronic Weight Management By Distribution Channel Retail Pharmacies Online/Direct-to-Consumer (DTC) By Region North America Europe Asia-Pacific Latin America Middle East & Africa For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at [email protected] Frequently Asked Questions Answer : The obesity GLP-1 market size is expected to increase from USD 8.21 billion in 2025 to USD 66.57 billion by 2035
Each category has characteristic pharmacokinetic behavior that is reflected in the half-life column of the peptide half-life chart above
)
DURATION, Diabetes therapy Utilization: Researching changes in A1c, weight and other factors Through Intervention with exenatide Once weekly
US$ 25.84
US$ 21.75
